Navigation Links
Carrington Subsidiary DelSite to Present at International Vaccine Conference in Ireland

Key Presentation by Dr. Yawei Ni, DelSite's CSO, Will Detail Antigen

Sparing and Immunoenhancing Attributes of GelSite(R) Polymer

IRVING, Texas, Oct. 3 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced that Dr. Yawei Ni, Chief Scientific Officer of DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, will make an key presentation titled "An Effective Adjuvant Based on a Novel In-situ Gelling Anionic Polysaccharide (GelSite(R) Polymer)" on November 13, 2007, at the second International Conference on Modern Vaccines/Adjuvants Formulation (MVAF) in Dublin, Ireland.

GelSite(R) polymer is a chemically and functionally distinct polygalacturonic acid (sodium salt) produced under cGMP to a purity of > 99%. It is uniquely capable of gelling in-situ at the administration site upon contact with body fluids at low polymer concentrations providing a sustained release mechanism of the active component. It is highly suited for the delivery of vaccines and therapeutics.

The presentation will discuss details of GelSite(R) polymer's immunoenhancing and antigen sparing effect following intramuscular injection. The GelSite(R) polymer is inert and non-immunostimulatory, but achieves its immunoenhancing and antigen-sparing effect through sustained release of vaccine antigens conferred by the in-situ gelation. It potentially represents a new class of adjuvants that act through the sustained release mechanism, rather than by immunostimulation.

Vaccines, one of the fast growing pharmaceutical segments, are projected to account for greater than $20 billion in sales in the next few years. Adjuvants are a critical component for vaccine development. Vaccines in a wide range of areas including infectious diseases and cancers are being developed by various companies, many of which will require adjuvants for optimal performance.

About MVAF 2007

MVAF 2007 will be an international forum for researchers and contributors from academic programs, industrial, governmental and regulatory groups interested in the future development and design of vaccines and adjuvants. The scientific program will include keynote lectures, contributed papers, workshops, panel discussions and poster presentations emphasizing all aspects of the usage and effectiveness of pharmaceutical development of vaccines and adjuvants, national and international regulatory guidelines, and safety issues with special emphasis on delivery/administration issues.

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc., is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institute of Health) under the Department of Health and Human Services.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
Breaking Medicine Technology: